Drug Eluting Balloons Market is predicted to reach USD 1.1 billion at a CAGR of 7.50% during the forecast period 2023-2032

Market Research Future (MRFR) has published on the “Global Drug Eluting Balloons Market”.

The Drug Eluting Balloons Market is estimated to register a CAGR of 7.50% during the forecast period of 2024 to 2032.

MRFR recognizes the following companies as the key players in the global Drug Eluting Balloons Market— Bayer AG, Medtronic, B. Braun Melsungen AG, Cook Medical, Inc., Boston Scientific Corporation, Becton, Dickson and Company, EuroCor, Terumo Corporation, Koninklijke Philips N.V.

Drug Eluting Balloons Market Highlights

The global Drug Eluting Balloons Market is expected to register a CAGR of 7.50% during the forecast period and is estimated to reach USD 1.1 billion by 2032.

The development of advanced drug eluting balloon catheters for minimally invasive operations, as well as other manufacturing technological advancements, are projected to drive market expansion in the coming years. Despite the high expense of procedures and materials, as well as the strict constraints imposed by regulatory bodies, the global market for drug eluting balloons is expected to grow gradually over the next few years. In addition, the market for drug eluting balloons is expected to grow as a result of increased government programs, research and development, and public awareness of cardiac problems.

Segment Analysis

The global Drug Eluting Balloons Market has been segmented based on product, technology, and end-user.

The market is segmented by product into Coronary Drug Eluting Balloon, Peripheral Drug Eluting Balloon, and Others. In 2023, the Peripheral Drug Eluting Balloon segment reported the highest income. The segment's rise is attributed to the increasing global prevalence of peripheral artery disease and market players' strong focus on the launch of novel peripheral indication products.

Based on technology, the global Drug Eluting Balloons Market has been segmented into Paccocath, FreePac, TransPax, EnduraCoat, and Others. In 2023, the TransPax category remained the market leader. TransPax coating provides a balance of hydrophobic and hydrophilic properties, allowing the balloon to deliver a sufficient therapeutic dose of Paclitaxel while minimizing systemic loss.

Based on end-user, the global Drug Eluting Balloons Market has been segmented into Hospitals and Ambulatory Surgery Centers, Cath Labs, and Others. In 2023, the Hospitals and Ambulatory Surgery Centers category will hold the greatest share of the global market due to the increased number of cardiac and peripheral illness treatments performed in hospitals and ambulatory surgery centers.

Explore In-depth Details: Drug Eluting Balloons Market Research Report

Regional Analysis

The global Drug Eluting Balloons Market, based on region, has been divided into North America, Europe, Asia-Pacific, and Rest of the World. North America consists of the US and Canada. The Europe Drug Eluting Balloons Market comprises of Germany, France, the UK, Italy, Spain, and the rest of Europe. The Drug Eluting Balloons Market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World Drug Eluting Balloons Market comprises the Middle East, Africa, and Latin America.

North America dominated the drug eluting balloon catheters market in 2023. The primary drivers driving market expansion in North America are the favorable reimbursement environment in the United States, the growing inclination for minimally invasive procedures, and the skyrocketing number of surgeries. Furthermore, increased public awareness of the necessity for surgical operations to treat chronic diseases and injuries is driving market growth.

Moreover, the Europe market accounted for a substantial portion of the market in 2023 and is expected to rise significantly over the forecast period. The increasing prevalence of peripheral artery disease in Europe, as well as the presence of major players such as MicroPort Medical (Group) Co., Ltd. and B. Braun SE, are driving market expansion.

Additionally, the Asia Pacific region is expected to grow the quickest during the forecast period. This can be attributed to increased healthcare spending and an increase in the prevalence of cardiovascular illnesses. According to Biomedcentral, one out of every five people in China suffers from cardiovascular disease. Furthermore, increased disposable income and an aging population in countries such as Japan and China are expected to fuel the regional market. The emergence of health tourism in emerging countries is also contributing to the industry's growth.

Furthermore, the rest of the world's Drug Eluting Balloons Market is divided into the Middle East, Africa, and Latin America. This growth is attributed to the region's increasing hospitalization rate and aging population. Furthermore, the presence of major market participants in the area will boost the market value and adoption rate of drug eluting balloon catheters.

Key Findings of the Study

• The global Drug Eluting Balloons Market is expected to reach USD 1.1 billion by 2032, at a CAGR of 7.50% during the forecast period.


• The Asia Pacific region is expected to grow the quickest during the forecast period. This can be attributed to increased healthcare spending and an increase in the prevalence of cardiovascular illnesses.


• In 2023, the Hospitals and Ambulatory Surgery Centers category held the greatest share of the global drug eluting balloons


• Bayer AG, Medtronic, B. Braun Melsungen AG, Cook Medical, Inc., Boston Scientific Corporation, Becton, Dickson and Company, EuroCor, Terumo Corporation, and Koninklijke Philips N.V. are the key market players.